linjc16/ctgov huggingface dataset:
Perception About Upper Limb Functional Recovery, Barriers & Use of Training Devices Among Indian Stroke Survivors.

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to evaluate perceptions regarding affected arm and hand function and their willingness to use devices to enhance upper limb functions among stroke survivors. The main question[s] it aims to answer are: what will the stroke survivor's perception of interventions and device development in his/her arm recovery? Wheather he is willing to use it for his arm recovery?

Detailed Description
-----------------
Individuals with stroke will be recruited from MGM Hospital and other hospitals from Aurangabad. Participants will be adults (age >30) with stroke and with the capacity to provide written or verbal informed consent, and the ability to communicate verbally/online/phone. Participants will be contacted via phone or email by a member of the research team. If needed personal interviews of the patients will be taken. The research team will consist of the author and one helper Physical Therapy student and the guide. All team members participating in the training will ensure consistency in communications with participants. All the participants will be provided with information about the study objectives and procedures and will be asked if they are willing to participate. If they consent, they will be given one of three options: Complete the survey via phone immediately Complete the survey online. In this case, they will be sent a link to their email to complete an online survey. Complete the survey via personal interview

Official Title
-----------------
Perception About Upper Limb Functional Recovery, Barriers & Use of Training Devices Among Stroke Survivors- A Cross-Sectional Survey

Conditions
-----------------
Stroke, Middle Cerebral Artery With Infarction, Rehabilitation, Upper Limb Recovery, Economic Burdon

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: First-ever stroke All stages of stroke Onset of a stroke at least 1 year ago Age group: 30 to 75 Both genders included Patients diagnosed with MCA (Middle Cerebral Artery) stroke Exclusion Criteria: Aphasia Patients who are unable to follow commands Patients with other neurological disorders such as Multiple sclerosis and Parkinson's disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self Structured Marathi language translated Version Questionnaire | It's a 69 item questionnaire to obtain the responses from the stroke survivors about their Upper limb recovery and use of devices for the same. The Obtained responses will be used for the analyze the willingness of stroke clients for use of devices for his/her upper limb arm recovery | One Month |
Qualitative Study About Psychedelics Using in Psychiatric Disorders

Study Overview
=================
Brief Summary
-----------------
This study is set up to better understand the current use of psychedelics in France in the general population. The present focus on individuals who have used any type of psychedelic drug in order to suppress or alleviate a psychiatric symptom in the context of a diagnosed pathology. The data are collected during a semi-structured interview and then studied in a thematic analysis.

Official Title
-----------------
Qualitative Study of the Self-administered Therapeutic Use of Psychedelics in People With Psychiatric Disorders

Conditions
-----------------
Psychiatric Disorder

Intervention / Treatment
-----------------
* Diagnostic Test: Interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with a psychiatric disorder by a psychiatrist or general practitioner Patients used psychedelic or related substances in order to treat psychiatric symptoms Patients have given their oral non-opposition Patients affiliated to a social security scheme Exclusion Criteria: Patients who don't speak or understand French Patients under protection, guardianship or curators

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients using psychedelic substances<br>Adult patients self-administering psychedelic substances in psychiatric disorders | Diagnostic Test: Interview<br>* An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Experiences of people using psychedelic substances | Experiences description of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Profile of people using psychedelic substances | The profile of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psychiatric disorder, Psychedelics
A Long-term Follow-up Study of Pulmonary Function Changes Using Phase-resolved Functional Lung MRI in Patients With COVID-19

Study Overview
=================
Brief Summary
-----------------
So far, the number of COVID-19 infections worldwide has exceeded 700 million. Long-term damage to the lungs is a major sequela of COVID infection. Pulmonary function testing is an important means for the evaluation of lung damage. MRI examinations with free breathing and no contrast agent can prevent patients from suffering from ionizing radiation damage caused by multiple CT examinations.

Official Title
-----------------
A Long-term Follow-up Study of Pulmonary Function Changes Using Phase-resolved Functional Lung MRI in Patients With COVID-19

Conditions
-----------------
Pulmonary Function

Intervention / Treatment
-----------------
* Diagnostic Test: Functional lung MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Older than 18 years; Sign the informed consent; Patients diagnosed with COVID-19 by nucleic acid test and survived to be discharged; Complete clinical data during hospitalization. Exclusion Criteria: Patients with bacterial pneumonia; Patients with MRI contraindications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Functional lung MRI|Functional lung MRI|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QDP, VDP | perfusion defect percentage, ventilation defect percentage | 6 months |
OCS DCD Heart + CAP Continued Follow-Up

Study Overview
=================
Brief Summary
-----------------
The objective of this post-approval study is to evaluate long-term outcomes of patients enrolled in the OCS DCD Heart and OCS DCD Heart CAP studies.

Official Title
-----------------
OCS DCD Heart + CAP Continued Follow-Up Post-Approval Study

Conditions
-----------------
Heart Transplant

Intervention / Treatment
-----------------
* Device: OCS Heart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients transplanted in the OCS DCD Heart Trial and OCS DCD Heart CAP trials.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: OCS Heart|Transplanted with OCS preserved heart.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient survival | Patient survival through 5 years post-transplant | 5 years post-transplant |
Pain Clinic Staff Harassed by Patients Pre/Post COVID

Study Overview
=================
Brief Summary
-----------------
Chronic pain may cause psychological or behavioral problems. Chronic pain patients occasionally harass the pain care providers. The COVID-19 pandemic caused major stress for the general population. Quantitative and qualitative analysis of prospective electronic and clinic diary data. Evaluation of incidents of clinic staff harassment; caused by patients, before and during COVID pandemic. Analysis of causative factors, incident outcome and lessons learned.

Detailed Description
-----------------
Chronic pain may be complicated by mental disease. Some patients have behavioral disorders and occasionally harass the pain care providers. The COVID-19 pandemic caused significant stress for the general population. The stress of the pandemic may aggravate the psychological dysfunction in chronic pain patients. This is a quantitative and qualitative analysis of prospective electronic and clinic diary data. It is an evaluation of incidents of pain clinic staff harassment; caused by patients, before and during the COVID pandemic. This is an analysis of incident causative factors, incident outcomes, systemic factors and lessons learned. The qualitative information of each incident is presented in a sensitive and careful format.

Official Title
-----------------
Pain Clinic Staff Harassment Perpetrated by Patients Pre/Post COVID Pandemic

Conditions
-----------------
Patient Violence

Intervention / Treatment
-----------------
* Behavioral: Behavioral therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult chronic pain patients Exclusion Criteria: pediatric chronic pain patients

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Behavioral therapy|Behavioral therapy and psychotherapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients who harassed clinic staff | Percentage of patients who harassed clinic staff | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Harassment by patient
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

Study Overview
=================
Brief Summary
-----------------
The aim of the trial is to establish a new regimen with Pembrolizumab and chemotherapy in the first line treatment of patients with advanced stage classical Hodgkin Lymphoma

Official Title
-----------------
Phase II Trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

Conditions
-----------------
Hodgkin Lymphoma

Intervention / Treatment
-----------------
* Drug: Pembrolizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Main Inclusion Criteria: age 18-60 advanced stage classical Hodgkin Lymphoma no previous treatment for cHL Main Exclusion Criteria: Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma Chemotherapy or radiotherapy in medical history Prior or concurrent disease that prevents treatment according to protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pembrolizumab|As induction therapy, all participants will receive one dose of single-agent pembrolizumab (P) followed by two cycles of chemo-immunotherapy consisting of pembrolizumab and an eBEACOPP variant without bleomycin (P-EACOPP). Response to induction therapy will be measured after P-mono (PET-1; only for scientific purposes) and after completion of 1x P and 2x P-EACOPP (PET-3). Further systemic treatment is PET-3-guided. Complete metabolic responses will be consolidated with two cycles of P-EACOPP while participants with a positive PET-3 will receive four cycles of P-EACOPP. PET-positive lesions after completion of chemo-immunotherapy will be recommended for consolidating radiotherapy according to standard of care.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression free survival |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
advanced stage, first line treatment, PD-1 inhibitor
Navigating the Clinical Research Process for Lymphoma

Study Overview
=================
Brief Summary
-----------------
Participation in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This trial will admit a wide range of data on the clinical trial experience of lymphoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future lymphoma patients.

Official Title
-----------------
Gaining Insights Into Patient Involvement Patterns and Trends in Participation in Lymphoma Clinical Trials

Conditions
-----------------
Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of lymphoma Participant must be 18 years of age or older Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study. Exclusion Criteria: Pregnant or lactating woman Participant is actively receiving study therapy in another Inability to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a lymphoma clinical research. |  | 3 months | 
| Number of lymphoma study participants who remain in clinical study until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lymphoma
Effect of Spinal Cord Stimulation (SCS) on Insulin Secretion in Humans

Study Overview
=================
Brief Summary
-----------------
This trial investigates the effect of BurstDR and tonic spinal cord stimulation (SCS) on glucose metabolism and heart rate variability in patients with neuropathic pain.

Detailed Description
-----------------
This study investigates the effect of spinal cord stimulation (BurstDR stimulation versus tonic stimulation versus no stimulation) on glucose metabolism, insulin secretion and heart rate variability in patients with neuropathic pain. To assess insulin secretion, hyperglycaemic clamps are performed in 10 patients. Three different stimulation conditions (BurstDR, tonic and no stimulation) are tested in 10 hyperglycaemic clamps each. A total of 30 clamps are carried out.

Official Title
-----------------
Effect of BurstDR and Tonic Spinal Cord Stimulation (SCS) on Glucose Metabolism in Patients With Neuropathic Pain

Conditions
-----------------
Spinal Cord Stimulation, Insulin Secretion

Intervention / Treatment
-----------------
* Device: BurstDR stimulation
* Device: Tonic stimulation
* Device: No stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: implanted BurstDR spinal cord stimulating system body mass index 18-25 kg/m2 Exclusion Criteria: neurological and psychatric diseases decompensated diabetes mellitus hemoglobin < 13 g/dl thrombocytopenia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BurstDR stimulation<br>BurstDR spinal cord stimulation during hyperglycemic clamp | Device: BurstDR stimulation<br>* BurstDR spinal cord stimulation<br>|
| Experimental: Tonic stimulation<br>Tonic spinal cord stimulation during hyperglycemic clamp | Device: Tonic stimulation<br>* Tonic spinal cord stimulation<br>|
| Placebo Comparator: No stimulation<br>No spinal cord stimulation during hyperglycemic clamp | Device: No stimulation<br>* Stimulator is switched off<br>* Other names: No spinal cord stimulation;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| First and second phase of insulin secretion | Modulation of insulin secretion by spinal cord stimulation | Insulinsecretion during clamp (2 hours) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Root Mean Square of Successive Differences (RMSSD) | Modulation of heart rate variability by spinal cord stimulation assessed by electrocardiography | Heart rate variablity during stimulation (10 minutes) |
Chinese Severe Brain Injury Trial

Study Overview
=================
Brief Summary
-----------------
Building a Large Chinese Cohort(Chinese Severe brain injury Trial）

Official Title
-----------------
Chinese Severe Brain Injury Trial

Conditions
-----------------
Severe Brain Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a clear cause of brain injury disorders of consciousness, GCS≤12 within six months of onset Exclusion Criteria: not applicable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| good prognosis group<br> | |
| poor prognosis group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glasgow Outcome Scale | The unabbreviated scale title is Glasgow Outcome Scale. GOS includes a score of 1-5, with the higher the score, the better the prognosis. | 6 months after severe Brain Injury | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glasgow Outcome Scale | The unabbreviated scale title is Glasgow Outcome Scale. GOS includes a score of 1-5, with the higher the score, the better the prognosis. | 3 months and 12 months after severe Brain Injury |
Registry Study of Assistive Devices, Medicines and Healthcare Measures in ALS, SMA and Other Neurological Diseases.

Study Overview
=================
Brief Summary
-----------------
This registry study aims to collect data on the provision of assistive devices, medicines, and other healthcare measures, such as ventilation therapy and nutrition support, in patients with Amyotrophic lateral sclerosis (ALS), Spinal muscular atrophy (SMA) and other neurological disorders. The data collected should describe the clinical practice, meaning real-world evidence and patient-reported outcomes.

Detailed Description
-----------------
This registry study aims to collect data on the provision of assistive devices, medicines, and other healthcare measures, such as ventilation therapy and nutrition support, in patients with ALS, SMA and other neurological disorders. The data collected should describe the clinical practice, meaning real-world evidence and patient-reported outcomes. The collected data include clinical characteristics, medical history, assessment scales, such as ALS functional rating scale-revised (ALSFRS-R), prognosis indicators, such as ALS progression rate, biomarker data, such as serum Neurofilament light chain (sNfL), genetic data, such as the mutation status of SOD1, FUS, c9orf72, TARDBP in ALS, SMN1 in SMA patients, innovative drugs such as Tofersen, Nusinersen, Risdiplam, as well as symptomatic drugs, patient-reported outcome data being captured using questionnaires and established clinical scales on medication expectation and treatment satisfaction.

Official Title
-----------------
Registry Study of the Provision of Assistive Devices, Medicines, and Other Healthcare Measures in an Inter-cohort Observation of Patients With ALS , SMA and Other Neurological Diseases.

Conditions
-----------------
Amyotrophic Lateral Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of a chronic neurological disease - Exclusion Criteria: Lack of cooperation and unwillingness to store and share medical data collected in the registry study -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The systematic recording of neurological treatment and its evaluation by patients via specific questionnaires | The systematic recording of neurological treatment and its evaluation by patients via specific questionnaires | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NfL, ALS Registry study, SMA Registry study, ALS medication and care registry study, SMA medication and care registry study, Neurofilament light chain, ALSFRS-R, ALS-App, ALS, APST Research, Biomarker, Tofersen, Nusinersen, Risdiplam